To this end, several groups have also explored the potential of using anti-EGFR monoclonal antibodies (cetuximab and nimotuzumab) with radiotherapy and chemotherapy in improving outcome of NPC patients but the results thus far, have been mixed5, 6, 7. The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.